Knight Therapeutics (TSE:GUD) Stock Price Up 0.6% – Should You Buy?

Shares of Knight Therapeutics Inc. (TSE:GUD) shot up 0.6% on Friday . The company traded as high as C$5.41 and last traded at C$5.37. 22,259 shares were traded during trading, a decline of 41% from the average session volume of 37,893 shares. The stock had previously closed at C$5.34.

Analysts Set New Price Targets

Separately, Raymond James raised Knight Therapeutics to a “moderate buy” rating in a report on Friday, November 15th.

Knight Therapeutics Stock Up 0.6 %

The company has a market capitalization of C$543.50 million, a P/E ratio of -26.85, a P/E/G ratio of -1,013.50 and a beta of 0.50. The business’s fifty day moving average price is C$5.33 and its 200 day moving average price is C$5.58. The company has a current ratio of 3.41, a quick ratio of 1.79 and a debt-to-equity ratio of 7.62.

Insider Buying and Selling at Knight Therapeutics

In other Knight Therapeutics news, Director Samira Sakhia acquired 20,000 shares of Knight Therapeutics stock in a transaction on Monday, November 11th. The shares were bought at an average price of C$5.15 per share, with a total value of C$103,000.00. Also, insider Sime Armoyan bought 90,300 shares of the company’s stock in a transaction on Tuesday, November 12th. The stock was bought at an average cost of C$5.13 per share, with a total value of C$463,672.44. Company insiders own 45.62% of the company’s stock.

Knight Therapeutics Company Profile

Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.